HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
Our vision is to ensure that we bring transformative products to Europe that add value and benefits to healthcare systems and patients.
The development and acquisition of innovative new products for the future is key to continue to build our pipeline.
We have a long-standing expertise in developing and commercialising our own products and those of our partners who have complementary skills and a shared vision for improving healthcare.
Our efforts are focused on unmet needs in specialist disease areas where we believe our skills and experience can make the most difference: gastroenterology, hepatology, cancer and supportive care.
We have a long standing expertise in gastroenterology – from macrogol-based laxatives to bowel preparation.
We are looking to bring innovative products to markets to improve adenoma detection rate (ADR*) through improved visualisation techniques and products including devices such as ENDOCUFF VISION®.
We are committed to the early detection and management of hepatic encephalopathy, a common and serious neuropsychiatric syndrome associated with cirrhosis.
In Europe 200,0001 people are affected by hepatic encephalopathy yet it remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. This results in poor quality of life for patients and a high burden on those who care for them.
Healthcare providers don’t always identify and treat the often subtle symptoms of hepatic encephalopathy which leads to mediocre patient outcomes and an increase in hospital admissions.
We are committed to improve the diagnosis of patients with head and neck cancer, the seventh most common type of cancer in Europe, with more than 150,000 new patients diagnosed in Europe in 2012.1
There are an estimated 400,000 to 600,000 new cases of all types of head and neck cancer globally each year and the mortality rate is between 223,000 and 300,000 deaths per year.2
We are also committed to ensuring early recognition of malignant hyperthermia an inherited, rare, life-threatening condition. Malignant hyperthermia is a rapid rise in body temperature which causes muscle stiffness and spasms and can occur during surgery with certain types of anesthesia.